Top-Rated StocksTop-RatedNASDAQ:APLS Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free APLS Stock Alerts $49.93 +1.21 (+2.48%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$48.62▼$50.4150-Day Range$47.51▼$71.7352-Week Range$19.83▼$94.75Volume1.25 million shsAverage Volume1.14 million shsMarket Capitalization$6.02 billionP/E RatioN/ADividend YieldN/APrice Target$77.93 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Apellis Pharmaceuticals alerts: Email Address Apellis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside56.1% Upside$77.93 Price TargetShort InterestBearish8.66% of Shares Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.46Based on 18 Articles This WeekInsider TradingSelling Shares$23.46 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.33) to $1.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.46 out of 5 starsMedical Sector100th out of 907 stocksPharmaceutical Preparations Industry34th out of 422 stocks 4.4 Analyst's Opinion Consensus RatingApellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.66% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently decreased by 1.42%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Apellis Pharmaceuticals is -1.27. Previous Next 1.9 News and Social Media Coverage News SentimentApellis Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Apellis Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 8 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,463,657.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.33) to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -11.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -11.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 30.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Apellis Pharmaceuticals Stock (NASDAQ:APLS)Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Read More APLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLS Stock News HeadlinesApril 16, 2024 | insidertrades.comThe 5 Stocks Most Sold By Insiders This Year (APLS)April 10, 2024 | insidertrades.comInsider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 69,107 Shares of StockApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 3, 2024 | insidertrades.comInsider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells 4,000 Shares of StockApril 25, 2024 | americanbankingnews.comZacks Research Research Analysts Lift Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)April 23, 2024 | globenewswire.comApellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial ResultsApril 20, 2024 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Expected to Post Q1 2024 Earnings of ($0.83) Per ShareApril 19, 2024 | americanbankingnews.comWedbush Weighs in on Apellis Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:APLS)April 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 19, 2024 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $57.00April 18, 2024 | benzinga.comBehind the Scenes of Apellis Pharmaceuticals's Latest Options TrendsApril 16, 2024 | americanbankingnews.comApellis Pharmaceuticals' (APLS) "Buy" Rating Reaffirmed at HC WainwrightApril 15, 2024 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from BrokeragesApril 11, 2024 | investing.comApellis Pharmaceuticals executive sells over $3.7m in stockApril 10, 2024 | benzinga.comApellis Pharmaceuticals Stock (NASDAQ:APLS), Quotes and News SummaryApril 10, 2024 | markets.businessinsider.comApellis Pharmaceuticals Hold Rating: Navigating Syfovre’s Mixed Reception and Emerging CompetitionApril 6, 2024 | nasdaq.comGuru Fundamental Report for APLSApril 4, 2024 | globenewswire.comApellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | globenewswire.comApellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 28, 2024 | finance.yahoo.comApellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?March 27, 2024 | markets.businessinsider.comDecoding 15 Analyst Evaluations For Apellis PharmaceuticalsMarch 27, 2024 | finance.yahoo.comInsider Sell: Chief Business & Strategy Officer Mark Delong Sells 9,913 Shares of Apellis ...March 21, 2024 | investing.comApellis Pharmaceuticals officer sells $564k in company stockMarch 16, 2024 | finance.yahoo.comAPLS Mar 2024 56.000 putMarch 16, 2024 | finance.yahoo.comAPLS Mar 2024 59.000 callMarch 16, 2024 | finance.yahoo.comAPLS Mar 2024 50.000 putMarch 15, 2024 | benzinga.comPeering Into Apellis Pharmaceuticals's Recent Short InterestSee More Headlines Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/25/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APLS CUSIPN/A CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees702Year Founded2009Price Target and Rating Average Stock Price Target$77.93 High Stock Price Target$106.00 Low Stock Price Target$54.00 Potential Upside/Downside+56.1%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($4.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-528,630,000.00 Net Margins-133.34% Pretax Margin-132.76% Return on Equity-178.60% Return on Assets-60.41% Debt Debt-to-Equity Ratio0.48 Current Ratio3.10 Quick Ratio2.50 Sales & Book Value Annual Sales$396.59 million Price / Sales15.18 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book30.45Miscellaneous Outstanding Shares120,580,000Free Float111,538,000Market Cap$6.02 billion OptionableOptionable Beta0.88 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Cedric Francois M.D. (Age 52)Ph.D., Co-Founder, President, CEO & Director Comp: $1.2MDr. Pascal Deschatelets Ph.D. (Age 54)Co-Founder & Chief Scientific Officer Comp: $688.05kMr. Alec Machiels J.D. (Age 51)MBA, Co-Founder & Director Comp: $72.5kMr. Timothy E. Sullivan (Age 53)CFO & Treasurer Comp: $716.41kMr. Adam J. Townsend (Age 46)Chief Operating Officer Comp: $701.61kMr. David O. Watson Esq. (Age 51)J.D., General Counsel Comp: $675.35kMr. James G. Chopas CPA (Age 57)VP, Corporate Controller & Chief Accounting Officer Ms. Meredith KayaSenior Vice President, Investor Relations & Strategic FinanceMs. Karen Lewis (Age 51)Chief People Officer Prof. Peter Hillmen M.D.Ph.D., Head of Hematology Engagement & Member of PNH Scientific Advisory BoardMore ExecutivesKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSBlueprint MedicinesNASDAQ:BPMCElanco Animal HealthNYSE:ELANCytokineticsNASDAQ:CYTKJazz PharmaceuticalsNASDAQ:JAZZView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 121,390 shares on 4/24/2024Ownership: 1.678%Simplicity Wealth LLCBought 78,247 shares on 4/24/2024Ownership: 0.065%Summit Trail Advisors LLCBought 4,465 shares on 4/23/2024Ownership: 0.004%Altfest L J & Co. Inc.Sold 1,205 shares on 4/22/2024Ownership: 0.003%Handelsinvest InvesteringsforvaltningSold 1,400 shares on 4/19/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions APLS Stock Analysis - Frequently Asked Questions Should I buy or sell Apellis Pharmaceuticals stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares. View APLS analyst ratings or view top-rated stocks. What is Apellis Pharmaceuticals' stock price target for 2024? 15 Wall Street research analysts have issued 12 month price objectives for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $54.00 to $106.00. On average, they expect the company's share price to reach $77.93 in the next year. This suggests a possible upside of 56.1% from the stock's current price. View analysts price targets for APLS or view top-rated stocks among Wall Street analysts. How have APLS shares performed in 2024? Apellis Pharmaceuticals' stock was trading at $59.86 at the start of the year. Since then, APLS shares have decreased by 16.6% and is now trading at $49.93. View the best growth stocks for 2024 here. When is Apellis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our APLS earnings forecast. How can I listen to Apellis Pharmaceuticals' earnings call? Apellis Pharmaceuticals will be holding an earnings conference call on Tuesday, May 7th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) posted its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.73) EPS for the quarter, hitting the consensus estimate of ($0.73). The company had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 178.60% and a negative net margin of 133.34%. The company's quarterly revenue was up 545.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.50) earnings per share. What ETFs hold Apellis Pharmaceuticals' stock? ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), Jacob Forward ETF (JFWD), First Trust BuyWrite Income ETF (FTHI), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).ProShares Ultra Nasdaq Biotechnology (BIB). What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO? 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI). When did Apellis Pharmaceuticals IPO? Apellis Pharmaceuticals (APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Apellis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.68%), Allspring Global Investments Holdings LLC (0.10%), Simplicity Wealth LLC (0.06%), Hennion & Walsh Asset Management Inc. (0.01%), Summit Trail Advisors LLC (0.00%) and Altfest L J & Co. Inc. (0.00%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Caroline Baumal, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown. View institutional ownership trends. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Apellis Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.Read More This page (NASDAQ:APLS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupWill this $2 AI stock double overnight?Behind the MarketsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
